Health Care • Biotechnology: Pharmaceutical Preparations
$1.75 ▼ -0.03
(-1.68%)
MKT CAP: $5.6M • VOL: 64.8K
52W L $1 52W H $12
ROARABLE / RQD
E • 32/100
PIOTROSKI
3 / 9
LGVN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.2M | $2.4M | $709.0K |
| YoY Revenue Growth % | -49.9% | +237.4% | — |
| Gross Profit | $803.0K | $1.9M | — |
| Gross Margin % | 67.0% | 78.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$23.3M | -$16.5M | -$21.0M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$22.7M | -$16.0M | -$21.4M |
| EBITDA (Normalized) | -$23.1M | -$16.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$18.6M | -$13.9M | -$19.0M |
| Capital Expenditures (CapEx) | $245.0K | $655.0K | — |
| Free Cash Flow (FCF) | -$18.9M | -$14.5M | -$19.0M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $4.7M | $19.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $5.7M | $21.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LGVN.